VASOCON by Novartis is clinical pharmacology naphazoline constricts the vascular system of the conjunctiva. First approved in 1971.
Drug data last refreshed 7h ago
CLINICAL PHARMACOLOGY Naphazoline constricts the vascular system of the conjunctiva. It is presumed that this effect is due to direct stimulation action of the drug upon the alpha adrenergic receptors in the arterioles of the conjunctiva resulting in decreased conjunctival congestion. Naphalozine…
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Impact of Aerobic Exercise Training on Sympathetic Vasoconstriction and Vascular Function in Essential Hypertension
Vasoconstriction Trial With LEO 90100 Aerosol Foam
A Vasoconstriction Study With LEO 90100
Dexmedetomidine and Hypoxic Pulmonary Vasoconstriction in Thoracic Surgical Procedures and One-Lung Ventilation
Susceptibility to High Altitude Pulmonary Edema in Subjects With Increased Hypoxic Pulmonary Vasoconstriction
Worked on VASOCON at Novartis? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.